Camille Debord
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Camille Debord has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Marion Eveillard
Hematology Biology Nantes University Hospital Nantes France
8 shared publications - Marie Christine Bene
Hematology Nantes University Hospital Nantes France
7 shared publications - Marc Fouassier
Nantes Université, CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, Nantes, France
5 shared publications Olivier Theisen
Hematology Laboratory CHU Nantes Germany
3 shared publicationsRobin Boutault
Hematology Laboratory CHU Nantes Germany
3 shared publicationsAntoine Babuty
Hematology Biology Department, Nantes University Hospital and CRCINA, Nantes, France
2 shared publications
Latest Publications
- 8 August 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (5) , 787-795
Prothrombin consumption as an indicator of hemorrhagic phenotype in mild platelet function disorders
Background: The bleeding risk of patients with mild platelet function disorders is difficult to assess and their phenotype remains ill‐explored.Aim: This study was designed to establish a comprehensive biological phenotype of patients with mild platelet function disorders.Methods: Twenty patients were included with persistent abnormal light transmission aggregometry (LTA). The ISTH bleeding assessment tool (ISTH‐BAT) was assessed to identify laboratory analyses associated with an abnormal hemorrhagic score.Results: The majority of patients had defects that might affect Gαi protein signaling pathways or minor abnormalities. No LTA nor flow cytometry parameters were associated with an above‐normal hemorrhagic score. However, prothrombin consumption, which corresponds to the ratio of serum residual factor II to plasma residual factor II, was significantly higher (p = .006) in the abnormal ISTH‐BAT group (mean = 14%, SD = 6) compared with the normal ISTH‐BAT group (mean = 8%, SD 4). Prothrombin consumption was significantly associated with ISTH‐BAT score (r = .5287, IC 95% 0.0986–0.7924, p = .0165).Conclusion: In this group of patients, there was an association between a pathological bleeding score and increased prothrombin consumption. This test could be used as an additional indicator of platelet function abnormality liable to be related to bleeding risk.
- 8 August 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (5) , 787-795
Prothrombin consumption as an indicator of hemorrhagic phenotype in mild platelet function disorders
Background: The bleeding risk of patients with mild platelet function disorders is difficult to assess and their phenotype remains ill‐explored.Aim: This study was designed to establish a comprehensive biological phenotype of patients with mild platelet function disorders.Methods: Twenty patients were included with persistent abnormal light transmission aggregometry (LTA). The ISTH bleeding assessment tool (ISTH‐BAT) was assessed to identify laboratory analyses associated with an abnormal hemorrhagic score.Results: The majority of patients had defects that might affect Gαi protein signaling pathways or minor abnormalities. No LTA nor flow cytometry parameters were associated with an above‐normal hemorrhagic score. However, prothrombin consumption, which corresponds to the ratio of serum residual factor II to plasma residual factor II, was significantly higher (p = .006) in the abnormal ISTH‐BAT group (mean = 14%, SD = 6) compared with the normal ISTH‐BAT group (mean = 8%, SD 4). Prothrombin consumption was significantly associated with ISTH‐BAT score (r = .5287, IC 95% 0.0986–0.7924, p = .0165).Conclusion: In this group of patients, there was an association between a pathological bleeding score and increased prothrombin consumption. This test could be used as an additional indicator of platelet function abnormality liable to be related to bleeding risk.
- 22 February 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (5) , 806-807
Suffering neutrophils… where is the enemy?
- 22 February 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (5) , 806-807
Suffering neutrophils… where is the enemy?
- 1 January 2021
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (1) , 285-287
Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma
- 1 January 2021
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (1) , 285-287
Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma
- 15 June 2020
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (S1) , 113-120
Flow cytometry in the diagnosis of mature B‐cell lymphoproliferative disorders
B‐lineage lymphoproliferative disorders (LPD) are rather frequent diseases, associated with specific clinical or biological features but also sometimes of fortuitous discovery. Multiparameter flow cytometry plays a major role for a rapid diagnostic indication, on peripheral blood or bone marrow samples in most instances, guiding complementary analyses and allowing for the proper therapeutic management of patients. After describing the important pre‐analytical precautions required for an adequate assessment, the immunophenotypic features of small‐cell and large‐cell lymphomas are described in this review. The ubiquitous expression of CD19 is a first mandatory gating step. A possible clonal proliferation is then suspected by the demonstration of surface immunoglobulin light chain restriction. The aberrant presence of CD5 allows to segregate chronic lymphocytic leukemia and mantle cell lymphoma in most cases. Other LPD exhibit specific immunophenotypic features. A table of useful markers and a decision tree are provided. Of note, immunophenotypic data should as much as possible be interpreted in an integrated manner, involving the patient's clinical and other biological features, and be completed by further chromosomal and/or molecular investigations.
- 15 June 2020
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (S1) , 113-120
Flow cytometry in the diagnosis of mature B‐cell lymphoproliferative disorders
B‐lineage lymphoproliferative disorders (LPD) are rather frequent diseases, associated with specific clinical or biological features but also sometimes of fortuitous discovery. Multiparameter flow cytometry plays a major role for a rapid diagnostic indication, on peripheral blood or bone marrow samples in most instances, guiding complementary analyses and allowing for the proper therapeutic management of patients. After describing the important pre‐analytical precautions required for an adequate assessment, the immunophenotypic features of small‐cell and large‐cell lymphomas are described in this review. The ubiquitous expression of CD19 is a first mandatory gating step. A possible clonal proliferation is then suspected by the demonstration of surface immunoglobulin light chain restriction. The aberrant presence of CD5 allows to segregate chronic lymphocytic leukemia and mantle cell lymphoma in most cases. Other LPD exhibit specific immunophenotypic features. A table of useful markers and a decision tree are provided. Of note, immunophenotypic data should as much as possible be interpreted in an integrated manner, involving the patient's clinical and other biological features, and be completed by further chromosomal and/or molecular investigations.
- 9 June 2020
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 98 (6) , 464-475
Platelet immunophenotyping in health and inherited bleeding disorders, a review and practical hints
Inherited platelet function disorders are rare hemorrhagic diseases. The gold standard for their exploration is optical aggregometry; however, investigations by flow cytometry (FCM) are being increasingly used. In this review, the physiology of platelets is first recalled, setting the stage for the compartments of platelets that can be apprehended by specific and appropriate labeling. As this requires some pre‐analytical precautions and specific analytical settings, a second part focuses on these characteristic aspects, based on literature and on the authors' experience in the field, for qualitative or quantitative explorations. Membrane labeling with antibodies to CD42a or CD41, respectively, useful to assess the genetic‐related defects of Glanzmann thrombocytopenia and Bernard Soulier syndrome are then described. Platelet degranulation disorders are detailed in the next section, as they can be explored, upon platelet activation, by measuring the expression of surface P‐Selectin (CD62P) or CD63. Mepacrin uptake and release after activation is another test allowing to explore the function of dense granules. Finally, the flip‐flop anomaly related to Scott syndrome is depicted. Tables summarizing possible FCM assays, and characteristic histograms are provided as reference for flow laboratories interested in developing platelet exploration.
- 9 June 2020
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 98 (6) , 464-475
Platelet immunophenotyping in health and inherited bleeding disorders, a review and practical hints
Inherited platelet function disorders are rare hemorrhagic diseases. The gold standard for their exploration is optical aggregometry; however, investigations by flow cytometry (FCM) are being increasingly used. In this review, the physiology of platelets is first recalled, setting the stage for the compartments of platelets that can be apprehended by specific and appropriate labeling. As this requires some pre‐analytical precautions and specific analytical settings, a second part focuses on these characteristic aspects, based on literature and on the authors' experience in the field, for qualitative or quantitative explorations. Membrane labeling with antibodies to CD42a or CD41, respectively, useful to assess the genetic‐related defects of Glanzmann thrombocytopenia and Bernard Soulier syndrome are then described. Platelet degranulation disorders are detailed in the next section, as they can be explored, upon platelet activation, by measuring the expression of surface P‐Selectin (CD62P) or CD63. Mepacrin uptake and release after activation is another test allowing to explore the function of dense granules. Finally, the flip‐flop anomaly related to Scott syndrome is depicted. Tables summarizing possible FCM assays, and characteristic histograms are provided as reference for flow laboratories interested in developing platelet exploration.
- Open Access
- 27 February 2020
- Published by Wiley in British Journal of Haematology
- Vol. 189 (4) , E117-E120
Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies
- 27 February 2020
- Published by Wiley in British Journal of Haematology
- Vol. 189 (4) , E117-E120
Open AccessBaseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies
- Open Access
- 11 September 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (18) , 1563
From Montreal to von Willebrand…
- 11 September 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (18) , 1563
Open AccessFrom Montreal to von Willebrand…
- Open Access
- 4 January 2019
- Published by Wiley in British Journal of Haematology
- Vol. 186 (1) , 157-159
A new case of heterozygous variant of the GP1BB gene responsible for macrothrombocytopenia
- 4 January 2019
- Published by Wiley in British Journal of Haematology
- Vol. 186 (1) , 157-159
Open AccessA new case of heterozygous variant of the GP1BB gene responsible for macrothrombocytopenia
- 8 November 2018
- Published by Wiley in British Journal of Haematology
- Vol. 183 (5) , 736-746
A novel complete blood count‐based score to screen for myelodysplastic syndrome in cytopenic patients
Summary: The diagnosis of myelodysplastic syndromes (MDS) is often challenging, time‐ and resource‐consuming. A thorough analysis of complete blood count (CBC) parameters could, however, help to screen for MDS among other causes of cytopenia. To test this hypothesis, 109 newly‐diagnosed MDS patients and 399 cytopenic patients older than 50 years with confirmed absence of MDS were enrolled in a prospective study. Multiparametric analysis highlighted three CBC parameters that were significantly different between the two cohorts: mean corpuscular volume, absolute neutrophil count and median neutrophil complexity and width of dispersion of the events measured (Ne‐WX), which were used to define an MDS‐CBC score. This score enables the prediction of MDS with 86% sensitivity and 88% specificity. The MDS‐CBC score excluded MDS in 89% of cytopenic controls. Moreover, high score values at MDS diagnosis significantly correlated with decreased event‐free (P = 0·02) and overall survival (P = 0·01). The power of this score was confirmed in an independent validation cohort (MDS n = 34, cytopenic controls n = 28). The MDS‐CBC score is an easy and fast tool to exclude or suspect MDS in unselected patients with cytopenia of unknown reasons at the time of analysis, by prompting blood smear examination. It may thus improve allocation of further MDS‐specific work‐up in patients with cytopenia at the time of CBC assessment.
- 8 November 2018
- Published by Wiley in British Journal of Haematology
- Vol. 183 (5) , 736-746
A novel complete blood count‐based score to screen for myelodysplastic syndrome in cytopenic patients
Summary: The diagnosis of myelodysplastic syndromes (MDS) is often challenging, time‐ and resource‐consuming. A thorough analysis of complete blood count (CBC) parameters could, however, help to screen for MDS among other causes of cytopenia. To test this hypothesis, 109 newly‐diagnosed MDS patients and 399 cytopenic patients older than 50 years with confirmed absence of MDS were enrolled in a prospective study. Multiparametric analysis highlighted three CBC parameters that were significantly different between the two cohorts: mean corpuscular volume, absolute neutrophil count and median neutrophil complexity and width of dispersion of the events measured (Ne‐WX), which were used to define an MDS‐CBC score. This score enables the prediction of MDS with 86% sensitivity and 88% specificity. The MDS‐CBC score excluded MDS in 89% of cytopenic controls. Moreover, high score values at MDS diagnosis significantly correlated with decreased event‐free (P = 0·02) and overall survival (P = 0·01). The power of this score was confirmed in an independent validation cohort (MDS n = 34, cytopenic controls n = 28). The MDS‐CBC score is an easy and fast tool to exclude or suspect MDS in unselected patients with cytopenia of unknown reasons at the time of analysis, by prompting blood smear examination. It may thus improve allocation of further MDS‐specific work‐up in patients with cytopenia at the time of CBC assessment.
- 15 April 2018
- Published by Wiley in Hematological Oncology
- Vol. 36 (3) , 607-609
CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5‐positive B‐cell neoplasms
- 15 April 2018
- Published by Wiley in Hematological Oncology
- Vol. 36 (3) , 607-609
CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5‐positive B‐cell neoplasms